Patents by Inventor Benjamin Pei-Chung Kuo

Benjamin Pei-Chung Kuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytochrome P450 3A inhibitors and enhancers
    Patent number: 7169763
    Abstract: The present invention provides cytochrome P450 3A (CYP3A) inhibitors and enhancers. Examples of the CYP3A inhibitors include free bases or pharmacologically acceptable salts of at least one of the following compounds: ?-naphthoflavone, ?-naphthoflavone, apigenin, baicalein, ?-myrcene, catechin, 3-phenylpropyl acetate, formononetin, gallic acid, hesperetin, hesperidin, isoquercitrin, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, quercitrin, swertiamarin, terpineol, and trans-cinnamaldehyde. Examples of the CYP3A enhancers include free bases or pharmacologically acceptable salts of at least one of the following compounds: apigenin, formononetin, and luteolin-7-glycoside. The CYP3A inhibitors can be used, alone or co-administered with a drug, to improve the drug bioavailability.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: January 30, 2007
    Inventors: Oliver Yoa-Pu Hu, Cheng-Huei Hsiong, Benjamin Pei-Chung Kuo, Li-Heng Pao
  • Cytochrome P450 3A inhibitors and enhancers
    Publication number: 20030166584
    Abstract: The present invention provides cytochrome P450 3A (CYP3A) inhibitors and enhancers. Examples of the CYP3A inhibitors include free bases or pharmacologically acceptable salts of at least one of the following compounds: &agr;-naphthoflavone, &bgr;-naphthoflavone, apigenin, baicalein, &bgr;-myrcene, catechin, 3-phenylpropyl acetate, formononetin, gallic acid, hesperetin, hesperidin, isoquercitrin, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, quercitrin, swertiamarin, terpineol, and trans-cinnamaldehyde. Examples of the CYP3A enhancers include free bases or pharmacologically acceptable salts of at least one of the following compounds: apigenin, formononetin, and luteolin-7-glycoside. The CYP3A inhibitors can be used, alone or co-administered with a drug, to improve the drug bioavailability.
    Type: Application
    Filed: February 22, 2002
    Publication date: September 4, 2003
    Inventors: Oliver Yoa-Pu Hu, Cheng-Huei Hsiong, Benjamin Pei-Chung Kuo, Li-Heng Pao